Inflammatory Cell Profiles in Early- and Late-Manifestation Immune Checkpoint Inhibitor Myocarditis | JACC: CardioOncology

Dr. Cristina Gil-Cruz discusses a JACC: CardioOncology study comparing early- and late-manifestation immune checkpoint inhibitor (ICI) myocarditis, where endomyocardial biopsies showed greater T-cell and macrophage infiltration in early cases despite similar left ventricular ejection fraction and fibrosis. She explains what these inflammatory cell profiles mean for cardio-oncology care, from immunosuppression and ICI rechallenge to balancing cardiac safety with effective cancer immunotherapy.